Tri Xenglu Xr 5mg/12.5mg/1000mg Tablet – Comprehensive Triple Action for Type 2 Diabetes Regulation
Tri Xenglu Xr 5mg/12.5mg/1000mg Tablet – Comprehensive Triple Action for Type 2 Diabetes Regulation
Description
Tri Xenglu Xr 5mg/12.5mg/1000mg Tablet – Extended-Release Support for Balanced Blood Glucose Levels
Tri Xenglu Xr 5mg/12.5mg/1000mg Tablet is a prescription antidiabetic medication featuring a triple combination of empagliflozin 5mg, linagliptin 12.5mg, and metformin hydrochloride extended-release 1000mg. This advanced formula addresses type 2 diabetes through multiple mechanisms: empagliflozin facilitates glucose elimination via the kidneys, linagliptin stimulates insulin secretion and suppresses glucagon to stabilize post-meal sugar spikes, and metformin lowers hepatic glucose production while boosting insulin sensitivity. As an extended-release tablet, it offers sustained release for consistent control, reducing the burden of multiple doses and supporting better adherence in daily routines. Unique to this variant, the adjusted dosing provides tailored therapy for patients who require specific glycemic adjustments, with clinical evidence of effective A1C lowering, potential weight benefits, and reduced cardiovascular risks when used as part of a holistic diabetes plan.
